Somatic tumour testing establishes that bilateral DICER1-associated ovarian Sertoli–Leydig cell tumours represent independent primary neoplasms

W. Glenn McCluggage, Anne Laure Chong, Leanne de Kock, William D. Foulkes

Research output: Contribution to journalArticle


Aims: Sertoli–Leydig cell tumours (SLCTs) are rare ovarian neoplasms that are commonly associated with somatic or germline DICER1 mutations, especially when of the moderately or poorly differentiated type. A large majority are unilateral, but bilateral neoplasms have been reported, sometimes in the context of germline DICER1 mutations (DICER1 syndrome). It is currently unknown whether these represent independent neoplasms or metastasis from one ovary to the other and we aimed to elucidate this. Methods and results: We report three cases of bilateral ovarian SLCT (all in patients with DICER1 syndrome) and review all reported cases of bilateral neoplasms. In the three cases (all moderately or poorly differentiated neoplasms), the time interval between the discovery of the tumours in each ovary ranged from 2.7 years to 6 years. In all cases, different DICER1 somatic hotspot mutations within the two tumours provided definitive proof that they represent independent neoplasms; this may be important clinically. Our literature review revealed that, when this information was available, all patients with bilateral SLCT had a germline DICER1 mutation. Conclusions: Bilateral ovarian SLCTs represent independent rather than metastatic neoplasms, and essentially always occur in the context of DICER1 syndrome.

Original languageEnglish
Pages (from-to)223-230
Number of pages8
Issue number2
Publication statusPublished - Aug 2020

Fingerprint Dive into the research topics of 'Somatic tumour testing establishes that bilateral <i>DICER1-</i>associated ovarian Sertoli–Leydig cell tumours represent independent primary neoplasms'. Together they form a unique fingerprint.

Cite this